Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
製造番号 | 種類 | 製品説明 | 構造 | 純度 | 特徴 |
---|---|---|---|---|---|
CX4-H5219 | Human | Human CXCR4 / CD184 Full Length Protein (VLP) | |||
CX4-H5269 | Human | Human CXCR4 / CD184 Protein, Fc Tag |
|
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Plerixafor | SDZ-SID-791; JM-3100; JKL-169; AMD-3100; PLR-001; LM-3100 | Approved | Genzyme Corp | Mozobil, Mobozil, 释倍灵 | Mainland China | Lymphoma, Non-Hodgkin; Multiple Myeloma | Genzyme Europe Bv | 2008-12-15 | Colorectal Neoplasms; Rejection of organ transplantation; Sarcoma, Ewing; Brain Neoplasms; Neuroblastoma; Leukopenia; Osteosarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Agranulocytosis; Lymphopenia; Pulmonary Fibrosis; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Pulmonary Disease, Chronic Obstructive; Granulomatous Disease, Chronic; Lymphoma; Anemia, Sickle Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Adenocarcinoma; Primary Graft Dysfunction; Hematopoietic stem cell transplantation (HSCT); Cystic Fibrosis; Wiskott-Aldrich Syndrome; Bone metastases; Hematologic Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Warts; Agammaglobulinemia; Infections; Hodgkin Disease; Fanconi Anemia; Neoplasms; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Pancreatic Neoplasms; Multiple Myeloma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
USL-311 | USL-311 | Ligand Pharmaceuticals Inc | Details | ||
PF-06747143 | PF-06747143 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
LEO-35299 | LEO-35299 | Leo Pharma A/S | Details | ||
Balixafortide | POL-6326 | Phase 1 Clinical | Polyphor Ltd | Breast Neoplasms | Details |
LY-2510924 | T-134; LY-2510924 | Eli Lilly And Company | Details | ||
CGT-1881 | CGT1881; CGT-1881 | Phase 1 Clinical | Cgenetech(Suzhou China) Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Lymphoma, Non-Hodgkin | Details |
PTX-9908 | PTX-9908 | Phase 2 Clinical | Pertinax Therapeutics | Carcinoma, Hepatocellular | Details |
X-4136 | X-4136 | Clinical | X4 Pharmaceuticals Inc | Lymphoma, B-Cell | Details |
NRP-2945 | NNZ-4945; NRP-2945 | Phase 2 Clinical | Neuren Pharmaceuticals Ltd | Epilepsy | Details |
68Ga-Pentixather | 68Ga-Pentixather | Phase 1 Clinical | Peking Union Medical College Hospital | Multiple Myeloma | Details |
Ulocuplumab | MDX-1338; BMS-936564 | Phase 2 Clinical | Bristol-Myers Squibb Company | Leukemia; Solid tumours; Multiple Myeloma; Lymphoma, Follicular; Leukemia, B-Cell; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
212-Lead Pentixather | Phase 1 Clinical | National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center | Small Cell Lung Carcinoma; Lung Neoplasms | Details | |
203-Lead Pentixather | Phase 1 Clinical | National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center | Small Cell Lung Carcinoma; Lung Neoplasms | Details | |
[68Ga]Pentixafor | Phase 2 Clinical | The University Of Iowa | Neuroendocrine Tumors; Central Nervous System Neoplasms | Details | |
JVS-100 | ACRX-100; GP-51801; GP51801; JVS-100; SRX-100 | Phase 1 Clinical | Cleveland Clinic | Heart Failure; Surgical Wound; Ischemia; Peripheral Arterial Disease | Details |
AD-214 | AD-214 | Phase 1 Clinical | Addpharma Inc, Adalta Ltd | Lung Diseases, Interstitial; Gastroesophageal Reflux | Details |
4-P-021 | 4P021; 4-P-021 | Phase 2 Clinical | 4P-Pharma Ltd, University of Bordeaux, Institut Pasteur De Lille | Coronavirus Disease 2019 (COVID-19) | Details |
GPC-100 | GPC-100 | Phase 2 Clinical | GPCR Therapeutics USA Inc | Multiple Myeloma | Details |
MB-1707 | MB-1707 | Phase 1 Clinical | Mainline Biosciences Inc | Solid tumours; Ovarian Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Motixafortide | 4F-Benzoyl-TN14003; TN-14003; TF-14016; BL-8040; BKT-140; GFH-168 | Phase 3 Clinical | Biokine | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Lymphoid; Esophageal Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Hodgkin Disease; Multiple Myeloma; Anemia, Aplastic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Adenocarcinoma; Anemia, Sickle Cell | Details |
Mavorixafor | AMD-11070; X4P-001-IO; AMD-070; X4P-001; X4P-001-RD; X4P-001-LD; ABSK-081 | Phase 3 Clinical | Genzyme Corp | HIV Infections; Carcinoma, Renal Cell; WHIM syndrome; Neutropenia; Triple Negative Breast Neoplasms; Waldenstrom Macroglobulinemia; Melanoma | Details |
This web search service is supported by Google Inc.